Aura Biosciences, Inc.

For the period ended Mar 31, 2026. Filed May 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

AURA$7.65-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	March 31, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$84,793	$59,515
Marketable securities	29,940	84,726
Prepaid expenses and other current assets	3,771	5,498
Total current assets	118,504	149,739
Restricted cash and deposits	768	768
Right-of-use assets - operating lease	15,416	15,828
Other long-term assets	517	471
Property and equipment, net	2,472	2,624
Total Assets	$137,677	$169,430
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	2,573	1,549
Short-term operating lease liability	3,267	3,243
Accrued expenses and other current liabilities	10,866	13,591
Total current liabilities	16,706	18,383
Long-term operating lease liability	13,724	14,134
Total Liabilities	30,430	32,517
Commitments and Contingencies (Note 12)
Stockholders’ Equity:
Common stock, $0.00001 par value, 150,000,000 authorized at March 31, 2026 and December 31, 2025, and 64,150,468 and 63,587,777 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	—	—
Additional paid-in capital	621,557	617,433
Accumulated deficit	(514,103)	(480,418)
Accumulated other comprehensive loss	(207)	(102)
Total Stockholders’ Equity	107,247	136,913
Total Liabilities and Stockholders’ Equity	$137,677	$169,430

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.